Track topics on Twitter Track topics that are important to you
Bagsværd, Denmark, 8 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 1 July 2019, the following transactions have been made under the programme:
|Accumulated, last announcement||4,468,000||1,464,295,863|
|1 July 2019||125,000||339.31||42,413,255|
|2 July 2019||128,000||342.91||43,892,487|
|3 July 2019||140,500||346.88||48,736,153|
|4 July 2019||135,900||342.54||46,551,012|
|5 July 2019||125,000||339.80||42,474,713|
|Accumulated under the programme||5,122,400||1,688,363,483|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 27,465,543 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 5 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 20,298,904 B shares at an average share price of DKK 326.29 per B share equal to a transaction value of DKK 6,623,317,084.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Kristoffer Due Berg (US)||+1 609 235 firstname.lastname@example.org|
Company announcement 40/2019
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...